1. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
- Author
-
Satoshi Kano, Kazuhiko Tsuchiya, Akihiro Homma, Koichi Yasuda, Satoshi Fukuda, Hiroki Shirato, Ichiro Kinoshita, Takatsugu Mizumachi, Jun Taguchi, Hiromitsu Hatakeyama, Rikiya Onimaru, Tomohiro Sakashita, Yasushi Shimizu, Hirotoshi Akita, and Tomohiko Kakizaki
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Docetaxel ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Mucositis ,Humans ,Head and neck cancer ,Aged ,Retrospective Studies ,Cisplatin ,Chemotherapy ,business.industry ,Induction chemotherapy ,Hematology ,General Medicine ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Head and neck squamous-cell carcinoma ,Radiation therapy ,Treatment Outcome ,Head and Neck Neoplasms ,Carcinoma, Squamous Cell ,Feasibility Studies ,Female ,Taxoids ,Surgery ,Fluorouracil ,business ,medicine.drug - Abstract
The aim of this study was to evaluate the feasibility of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Between 2010 and 2013, 30 patients with Stage IV HNSCC were treated in Hokkaido University Hospital with three cycles of induction chemotherapy (docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), day 1; and 5-fluorouracil 750 mg/m(2)/day 120 h continuous infusion, every 3 weeks) followed by concurrent weekly cisplatin (40 mg/m(2), on weeks 1, 2, 3, 5, 6 and 7) chemoradiotherapy. Three courses of induction chemotherapy were performed in 25 patients (83 %) with grade 3-4 toxicities during induction chemotherapy observed in 22 patients (73 %). The major toxicities were hematologic, with 22 cases (73 %) showing grade 3-4 neutropenia. Radiotherapy was completed (70 Gy) in 29 patients (97 %), while a total of 19 patients (63 %) completed five (13 patients) or six (6 patients) courses of chemotherapy. During concurrent chemoradiotherapy, no grade 4 hematological toxicities were observed. Grade 4 dermatitis was observed in one patient, and grade 3 mucositis was observed in 12 patients. There were no treatment-related deaths during the induction chemotherapy or concurrent chemoradiotherapy. The 1- and 2-year progression-free survival rates and the 1- and 2-year overall survival rates were 86 %, 72 %, and 89 %, 81 %, respectively. Sequential therapy composed of induction chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy is feasible, showing encouraging results in patients with locally advanced HNSCC. Concurrent weekly cisplatin chemoradiotherapy following induction chemotherapy appears to be a suitable alternative to three-weekly high-dose cisplatin therapy.
- Published
- 2015